Loading
Life sciences · Journal article
Journal of Chemical Information and Modeling · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract The glucagon-like peptide-1 receptor (GLP-1R) plays a central role in metabolic regulation and is a major therapeutic target for obesity and diabetes. Peptide agonists, like semaglutide, targeting GLP-1R, remain among the most effective regulators of glucose metabolism and appetite. Nonetheless, recent reports of weight regain after treatment discontinuation sustain the interest in expanding the chemical diversity of GLP-1R ligands through drug discovery strategies. However, the structural complexity and conformational plasticity of class B1 G protein-coupled receptors (GPCRs) make conventional single-method virtual screening approaches prone to bias and limited chemotype recovery. Using an integrated ligand- and structure-based virtual screening pipeline, combining complementary ligand-based descriptors, multifingerprint similarity, electrostatic similarity, pharmacophore modeling, and multiconformation docking under a consensus-driven selection strategy, we identified three chemically distinct GLP-1R agonists comprising one nonpeptidic molecule (GQB47810), and two peptides (neuromedin C and DPDPE). Among them, DPDPE showed the greatest effectiveness, reaching nearly 100% of the maximal GLP-1 response, although with lower potency (EC50 = 4.3 μM). Further in vitro characterization confirmed that DPDPE behaved as a full agonist and exhibited dual agonistic activity at GLP-1R and at the glucose-dependent insulinotropic polypeptide receptor (GIPR, EC50 = 4.3 μM). Site-directed mutagenesis of the predicted binding site, with cell-surface expression measured for every mutant, and whole-cell competition binding against 125I-GLP-1 are consistent with direct engagement of the receptor. These findings establish a consensus-driven computational framework for chemotype-diverse agonist discovery at conformationally flexible GPCR targets and reveal a pentapeptide with GLP-1-like efficacy as a promising lead for next-generation small peptide therapeutics.